References

• Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., Furberg, C. D., . . . Harrington, R. A. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology, 52(18), 1502- 1517.
• Choy, E. (2012). Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology, 51(suppl_5), v3-v11. doi: 10.1093/rheumatology/kes113
• Clements, J. N. (2011). Tretment of rheumatoid arthritis: A review of recommendation and emergening therapy Formulary journal locum tenens, 1-7.
• Cooles, F. A., & Isaacs, J. D. (2011). Pathophysiology of rheumatoid arthritis. Current opinion in rheumatology, 23(3), 233-240.
• Cooles, F. A., & Isaacs, J. D. (2011). Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol, 23(3), 233-240. doi: 10.1097/BOR.0b013e32834518a3
• Daniels, S., Robbins, J., West, C. R., & Nemeth, M. A. (2009). Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther, 31(6), 1192-1208. doi: 10.1016/j.clinthera.2009.06.003
• Dong, Q. L., Geoffrey, T., Jun, T., & Dong, W. (2008). The development of novel therapies for rheumatoid arthritis. eExpert opinion on therapeutic patents, 18(7), 723-738.
• Fidahic, M., Jelicic Kadic, A., Radic, M., & Puljak, L. (2017). Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev, 6, Cd012095. doi: 10.1002/14651858.CD012095.pub2
• Friedewald, V. E., Bennett, J. S., Christo, J. P., Pool, J. L., Scheiman, J. M., Simon, L. S., . . . Roberts, W. C. (2010). AJC Editor's consensus: Selective and nonselective nonsteroidal anti- inflammatory drugs and cardiovascular risk. The American journal of cardiology, 106(6), 873-884.
• Futagami, S., Suzuki, K., Hiratsuka, T., Shindo, T., Hamamoto, T., Ueki, N., . . . Sakamoto, C. (2007). Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacology, 15(1), 1- 4. doi: 10.1007/s10787-006-1541-5
• Hu, P. J., Yu, J., Zeng, Z. R., Leung, W. K., Lin, H. L., Tang, B. D., . . . Sung, J. J. Y. (2004). Chemoprevention of gastric cancer by celecoxib in rats. Gut, 53(2), 195-200. doi: 10.1136/gut.2003.021477
• Kahlenberg, J. M., & Fox, D. A. (2011). Advances in the Medical Treatment of Rheumatoid Arthritis. Hand clinics, 27(1), 11-20. doi: 10.1016/j.hcl.2010.09.002
• Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj, 332(7553), 1302-1308.
• Kısmet, K., Akay, M. T., Abbasoǧlu, O., & Ercan, A. (2004). Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detection and Prevention, 28(2), 127-142. doi:
• Klarenbeek, N. B., Kerstens, P. J. S. M., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2010). Recent advances in the management of rheumatoid arthritis. BMJ (Clinical research ed.), 341, c6942. http://europepmc.org/abstract/MED/21177351
• Ma, M. H., Kingsley, G. H., & Scott, D. L. (2010). A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford), 49(1), 91-98. doi: 10.1093/rheumatology/kep331
• Maqbool, I., Akhtar, M., Ahmad, R., Sadaquat, H., Noreen, S., Batool, A., & Khan, S. U. (2020). Novel multiparticulate pH triggered delayed release chronotherapeutic drug delivery of celecoxib-β-cyclodextrin inclusion complexes by using Box-Behnken design. European journal of pharmaceutical sciences, 146, 105254.
• McInnes , I. B., & Schett , G. (2011). The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine, 365(23), 2205- 2219. doi: 10.1056/NEJMra1004965
• O'dell, J. R. (2004). Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine, 350(25), 2591-2602.
• Silman, A. J., & Pearson, J. E. (2002). Epidemiology and genetics of rheumatoid arthritis. Arthritis Research, 4(Suppl 3), S265-S272. doi: 10.1186/ar578
• Smolen, J. S., & Steiner, G. (2003). Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov, 2(6), 473-488. doi:
• Steiner, G., & Smolen, J. (2002). Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Research, 4(Suppl 2), S1- S5. doi: 10.1186/ar551
• van Laar, M., Pergolizzi Jr, J. V., Mellinghoff, H.-U., Merchante, I. M., Nalamachu, S., O'Brien, J., . . . Raffa, R. B. (2012). Pain treatment in arthritis- related pain: beyond NSAIDs. The open rheumatology journal, 6, 320.
• Verstappen, S. M. M., Jacobs, J. W. G., Bijlsma, J. W. J., Heurkens, A. H. M., van Booma-Frankfort, C., Borg, E. J. t., . . . van der Veen, M. J. (2003). Five-year followup of rheumatoid arthritis patients after early treatment with disease- modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis & Rheumatism, 48(7), 1797-1807. doi: 10.1002/art.11170
• Walker, C., Essex, M. N., Li, C., & Park, P. W. (2016). Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. Journal of International Medical Research, 44(3), 483- 495. doi: 10.1177/0300060516628704
• Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine, 95(20), e3585. doi: 10.1097/md.0000000000003585
• Zwerina, J., Redlich, K., Schett, G., & Smolen, J. S. (2005). Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci, 1051, 716-729. doi: 10.1196/annals.1361.116